Carl Zeiss Meditec Reports Revenue Growth and Stable Operating Profit in First Half of Fiscal Year

JENA, Germany—Leading medical technology company Carl Zeiss Meditec AG (ISIN: DE0005313704) has announced financial results for the first six months of its 2024/2025 fiscal year ending March 31, 2025. The company reported revenue of €1,050.5 million during the period, compared with €947.2 million in the prior year, corresponding to growth of 10.9 percent. Adjusted for currency and acquisition effects, revenue was slightly below the prior year figure by 0.5 percent. Order entry increased by 33.4 percent, the company said. EBITA increased to approximately €113.6 million, compared with the prior-year period at €113.2 million, and the EBITA margin was 10.8 percent, compared with 12.0 percent the prior year.